Nektar Therapeutics Successfully Completes $115 Million Offering

Author: Logan Wright Updated: 07-02-2025 04:25 PM

Nektar Therapeutics Completes Public Offering of $115 Million

Nektar Therapeutics (NASDAQ: NKTR), a biotechnology company dedicated to advancing innovative therapies in immunotherapy, has successfully closed its underwritten public offering, raising a substantial $115 million. This funding arises from the sale of 4,893,618 shares of common stock, which included 638,298 shares sold as a result of the underwriters fully exercising their option to purchase additional shares at a public offering price of $23.50 per share.

Allocation of Proceeds for Future Growth

The funds generated from this offering will enable Nektar to focus on various corporate purposes, particularly in enhancing their research and development. This includes essential costs associated with clinical development and manufacturing needed to propel their promising drug candidates towards market readiness.

Key Players Behind the Offering

Nektar Therapeutics partnered with several financial institutions to facilitate this successful offering. The joint bookrunning managers were Jefferies and Piper Sandler, while BTIG, LLC served as a bookrunner. H.C. Wainwright & Co. took the lead manager role, ensuring a well-structured process throughout the offering.

Company Commitment to Transparency

The shares of common stock were issued under a previously filed shelf registration statement with the appropriate regulatory bodies. Nektar has committed to transparency by providing detailed documentation related to the terms of this offering and ensures all information is accessible to interested investors.

About Nektar Therapeutics

Nektar Therapeutics is renowned for its innovative approaches to treating autoimmune and chronic inflammatory diseases. Its leading product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a pioneering regulatory T cell stimulator currently undergoing evaluation in two Phase 2b clinical trials targeting atopic dermatitis and alopecia areata. In addition, Nektar's portfolio features several other promising candidates, such as NKTR-0165 and NKTR-0166, intended to stimulate the immune response against cancer and enhance treatment options in immunotherapy.

Continued Commitment to Development

As Nektar Therapeutics moves forward, it aims to leverage this funding to boost its pipeline and further enhance its clinical trials. The company remains dedicated to pushing the boundaries of immunotherapy and exploring the potential of its drug candidates to treat patients suffering from various conditions.

Frequently Asked Questions

What is the total amount raised by Nektar Therapeutics?

Nektar Therapeutics raised a total of $115 million through its public offering.

What will the raised funds be used for?

The funds will support research and development, clinical development, and manufacturing costs for Nektar Therapeutics' drug candidates.

Who managed the public offering?

The offering was managed by Jefferies, Piper Sandler, and BTIG, LLC, among others.

What is rezpegaldesleukin?

Rezpegaldesleukin (REZPEG or NKTR-358) is Nektar's lead product candidate, designed to stimulate regulatory T cells for treating autoimmune diseases.

How does Nektar Therapeutics ensure transparency in its offerings?

Nektar Therapeutics provides necessary documentation relating to its offerings through filings with the appropriate regulatory bodies.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.